Manipulating Stem Cells to Treat Calcification Pharmacological Regulation of in-situ Tissue Stem Cells Differentiation for Soft Tissue Calcification Treatment.

Jiajie Hu,Zi Yin,Weiliang Shen,Yu‐Bin Xie,Ting Zhu,Ping Lu,Youzhi Cai,Min‐Jian Kong,Boon Chin Heng,Yi Ting Zhou,Weishan Chen,Xiao Chen,Hongwei Ouyang
DOI: https://doi.org/10.1002/stem.2306
IF: 5.845
2016-01-01
Stem Cells
Abstract:Calcification of soft tissues, such as heart valves and tendons, is a common clinical problem with limited therapeutics. Tissue specific stem/progenitor cells proliferate to repopulate injured tissues. But some of them become divergent to the direction of ossification in the local pathological microenvironment, thereby representing a cellular target for pharmacological approach. We observed that HIF-2alpha (encoded by EPAS1 inclined form) signaling is markedly activated within stem/progenitor cells recruited at calcified sites of diseased human tendons and heart valves. Proinflammatory microenvironment, rather than hypoxia, is correlated with HIF-2alpha activation and promoted osteochondrogenic differentiation of tendon stem/progenitor cells (TSPCs). Abnormal upregulation of HIF-2alpha served as a key switch to direct TSPCs differentiation into osteochondral-lineage rather than teno-lineage. Notably, Scleraxis (Scx), an essential tendon specific transcription factor, was suppressed on constitutive activation of HIF-2alpha and mediated the effect of HIF-2alpha on TSPCs fate decision. Moreover, pharmacological inhibition of HIF-2alpha with digoxin, which is a widely utilized drug, can efficiently inhibit calcification and enhance tenogenesis in vitro and in the Achilles's tendinopathy model. Taken together, these findings reveal the significant role of the tissue stem/progenitor cells fate decision and suggest that pharmacological regulation of HIF-2alpha function is a promising approach for soft tissue calcification treatment. Stem Cells2016;34:1083-1096
What problem does this paper attempt to address?